"Ct"

Recently, the US FDA has granted orphan drug status to two new therapeutics in a row. One is a small molecule inhibitor, PCLX-001, for the treatment of acute myeloid leukaemia; the other is a T-cell therapy, ET140203, for the treatment of hepatoblastoma. Both therapies are currently in relevant trials.

On April 4, 2015, the 100-year-old active swimmer Mieko Nagaoka (living in Tabushi Town, Yamaguchi Prefecture, Japan) successfully completed the women's 1500-meter freestyle competition and became the world's first swimmer in the age group of 100-104.

On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!

PET/CT and PET/MRI, the world's leading-edge imaging screening devices, have extremely significant advantages in the early screening and diagnosis of a wide range of benign and malignant tumours throughout the body, the nervous system and the cardiovascular system, and can detect tumours as small as millimetres, especially useful for the early detection and treatment of liver cancer, breast cancer and pancreatic cancer. Translated with www.DeepL.com/Translator (free version)

The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial

CAR-T therapy is a cellular immunotherapy treatment that has become very popular in recent years. This therapy uses genetic engineering techniques to upgrade the patient's immune T cells in vitro, before entering the body to exert a powerful anti-cancer effect. Currently, CAR-T therapy has performed very well in blood cancers such as lymphoma and leukaemia.

Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

Every disease has a cause, and we are all sick because of various factors. Understanding the causes of diseases can help us to prevent them, which will help our health a lot.